Advertisement

Dermatika und Wundbehandlungsmittel

  • Uwe Fricke

Zusammenfassung

Dermatika zählen in Deutschland zu den verordnungsstärksten Arzneimitteln. Am häufigsten werden — wie in den Vorjahren — die Corticosteroid-externa verordnet. Die Wundbehandlungsmittel nehmen dagegen einen weniger bedeutsamen Rang ein.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P et al. (1994): Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977–981.PubMedCrossRefGoogle Scholar
  2. Ammon HPT, Sabieraj J, Kaul R (1996): Kamille. Mechanismus der antiphlogistischen Wirkung von Kamillenextrakten und-inhaltsstoffen. Dtsch Apoth Ztg 136:1821–1834.Google Scholar
  3. Anonymus (2002): New treatments for actinic keratoses. Medical Letter 44:57–58.Google Scholar
  4. Arens M, Travis S (2000): Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J Clin Microbiol 38:1758–1762.PubMedGoogle Scholar
  5. Arzneimittelkommission der deutschen Ärzteschaft (1999): Nutzen und Risiken durch Fumarsäure-Ester bei der Therapie der Psoriasis. Dtsch Ärztebl 96: A–721.Google Scholar
  6. Arzneimittelkommission der deutschen Ärzteschaft (2000): Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft. Dtsch Ärztebl 97: A3212.Google Scholar
  7. Asadullah K, Schmid H, Friedrich M, Randow F, Volk H-D, Sterry W, Döcke W-D (1997): Influence of monomethylfumarate on monocytic cytokine formation — explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 289: 623–630.PubMedCrossRefGoogle Scholar
  8. Aschoff R, Wozel G, Meurer M (2003): Aktuelle Aspekte der topischen Psoriasisbehandlung. Hautarzt 54: 237–241.PubMedCrossRefGoogle Scholar
  9. Asha VV, Pushpangadan P (1999): Antipyretic activity of Cardiospermum halicacabum. Indian J Exp Biol 37: 411–414.PubMedGoogle Scholar
  10. Ashcroft DM, Li Wan Po A, Griffiths CEM (2000a): Therapeutic strategies for psoriasis. J Clin Pharm Ther 25:1–10.PubMedCrossRefGoogle Scholar
  11. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM (2000b): Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Brit Med J 320:963–967.PubMedCrossRefGoogle Scholar
  12. Babilas P, Landthaler M, Szeimies R-M (2003): Die aktinische Keratose. Hautarzt 54: 551–562.PubMedGoogle Scholar
  13. Balasubramaniam P, Stevenson 0, Berth-Jones J (2004): Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 150: 741–746.PubMedCrossRefGoogle Scholar
  14. Belmin J, Meaume S, Rabus MT Bohbot S for The Investigators of the Sequential Treatment of the Elderly with Pressure Sores (STEPS) Trial. (2002): Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: a multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressings alone. J Am Geriatr Soc 50:269–274.PubMedCrossRefGoogle Scholar
  15. Biro K, Thaci D, Ochsendorf FR, Kaufmann R, Boehncke W-H (2003): Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis 49: 80–84.PubMedCrossRefGoogle Scholar
  16. Bradley M, Cullum N, Sheldon T (1999): The debridement of chronic wounds: a systematic review. Health Technol Assess 3:1–78.PubMedGoogle Scholar
  17. Braun-Falco O, Plewig G, Wolff HH (1995): Dermatologie und Venerologie, 4. Aufl Springer-Verlag, Berlin Heidelberg New York.Google Scholar
  18. Brogden RN, Goa KL (1997): Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 53: 511–519.PubMedCrossRefGoogle Scholar
  19. Bundesgesundheitsamt (1988): Monographie Fumarsäuremonoalkylester, Fumarsäuredialkylester, Fumarsäure und Fumarsäuresalze. Bundesanzeiger vom 11.10.1988, Nr. l91.Google Scholar
  20. Bundesgesundheitsamt (1993): Monographie Steinkohlenteer. Bundesanzeiger 45:845.Google Scholar
  21. Bundesinstitut für Arzneimittel und Medizinprodukte (2001): Schreiben vom 1.6.2001.Google Scholar
  22. Byrne A, Hnatko G (1995): Depression associated with isotretinoin therapy. Can J Psychiatry 40: 567.PubMedGoogle Scholar
  23. Carboni I, de Felice C, de Simoni I, Soda R, Chimenti S (2004): Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatol Treat 15: 23–26.CrossRefGoogle Scholar
  24. Cather J, Menter A (2002) Novel therapies for psoriasis. Am J Clin Dermatol 3: 159–173.PubMedCrossRefGoogle Scholar
  25. Chaffman MO (1999): Topical corticosteroids: A review of properties and principles in therapeutic use. Nurse Practitioner Forum 10:95–105.PubMedGoogle Scholar
  26. Chamberlain AJ, Kurwa HA (2003): Photodynamic therapy. Is it a valuable treatment option for actinic keratoses? Am J Clin Dermatol 4:149–155.PubMedCrossRefGoogle Scholar
  27. Christiansen JV, Gadborg E, Kleiter I, Ludvigsen K, Meier CH, Norholm A et al. (1977): Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial. Dermatologica 154:177–184.PubMedCrossRefGoogle Scholar
  28. Daschner F (1987): Sind Lokalantibiotika bei Hautinfektionen sinnvoll? Arzneiverordnung 4:41–46.Google Scholar
  29. De Jong R, Bezemer AC, Zomerdijk TPL, van de Pouw-Kraan T, Ottenhoff THM, Nibbering PH (1996): Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 26: 2067–2074.PubMedCrossRefGoogle Scholar
  30. Del Rosso JQ (2002): A status report on the medical management of rosacea: Focus on topical therapies. Cutis 70:271–275.PubMedGoogle Scholar
  31. Deutsche Dermatologische Gesellschaft (1998): Akne und ihre Subtypen. Leitlinien der Deutschen Dermatologischen Gesellschaft. AWMF-Leitlinien-Register Nr. 013/017 (http://www.uni-duesseldorf.de/AWMF/II/derm-008).Google Scholar
  32. Deutsche Dermatologische Gesellschaft (2003): Topische Dermatotherapie mit Glukokortikoiden — Therapeutischer Index. Leitlinien der Deutschen Dermatologischen Gesellschaft. AWMF-Leitlinien-Register Nr. 013/034 (http://www.uniduesseldorf.de/AWMF/II/derm-034.htm ).Google Scholar
  33. Ebner F, Heller A, Rippke F, Tausch I (2002): Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3:427–433.PubMedCrossRefGoogle Scholar
  34. Eisenbud D, Hunter H, Kessler L, Zulkowski K (2003): Hydrogel wound dressings: where do we stand in 2003? Ostomy Wound Manage 49: 52–57.PubMedGoogle Scholar
  35. Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y et al. (2003): International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 148(Suppl 63): 3–10.PubMedCrossRefGoogle Scholar
  36. Feldman S (2000): Advances in psoriasis treatment. Dermatol. Online J 6:4.PubMedGoogle Scholar
  37. Ferguson J (2002): What is the role of narrowband UVB in the treatment of psoriasis? Photodermal. Photoimmunol. Photomed. 18: 42–43.CrossRefGoogle Scholar
  38. Fine JD, Johnson L (1988): Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex. A double-blind placebo-controlled crossover trial. Arch Dermatol 124:1669–1672.PubMedCrossRefGoogle Scholar
  39. Fricke U, Klaus W (1985): Die neuen Arzneimittel — Wirkungsweise und therapeutischer Stellenwert. Eine Übersicht von Januar 1983 — Juni 1984. Offizinpharmazie 10:1–71.Google Scholar
  40. Fricke U, Klaus W (1991): Neue Arzneimittel 1990/91. Fortschritte für die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft, Stuttgart.Google Scholar
  41. Gehring W, Gloor M (1989): Cardiospermum — Ein neuer pflanzlicher Wirkstoff in der Dermatologie? H+G Ztschr Hautkrankh 64: 274–278.Google Scholar
  42. George A, Rubin G (2003): A systematic review and mety-analysis of treatments for impetigo. Br J Gen Pract 53:480–487.PubMedGoogle Scholar
  43. Gerritsen M J, van de Kerkhof PC, Langner A (2001): Long-term safety of topical calcitriol 3 microg g(-l) ointment. Br J Dermatol 144(Suppl 58): 17–19.PubMedGoogle Scholar
  44. Gibbs S, Harvey I, Sterling JC, Stark R (2004): Local treatments for cutaneous warts (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.Google Scholar
  45. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K (1999): A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0,05%) and erythromycin (2%) with gels containing isotretinoin (0,05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 199: 242–247.PubMedCrossRefGoogle Scholar
  46. Gloor M (1982): Pharmakologie dermatologischer Externa. Springer-Verlag, Berlin Heidelberg New York.CrossRefGoogle Scholar
  47. Gniazdowska B, Rueff F, Przybilla B (1999): Delayed contact hypersensitivity to nonsteroidal anti-inflammatory drugs. Contact Dermatitis 40:63–65PubMedCrossRefGoogle Scholar
  48. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002): Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205:46–53.PubMedCrossRefGoogle Scholar
  49. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D (2003): Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 49(1 Suppl): S1–37.PubMedCrossRefGoogle Scholar
  50. Gollnick HP, Krautheim A (2003): Topical treatment in acne: current status and future aspects. Dermatology. 206:29–36.PubMedCrossRefGoogle Scholar
  51. Gordon PM, Diffey BL, Matthews JNS, Farr PM (1999): A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 41: 728–732.PubMedCrossRefGoogle Scholar
  52. Goulden V (2003): Guidelines for the management of acne vulgaris in adolescents. Paediatr. Drugs 5: 301–313.PubMedGoogle Scholar
  53. Greaves MW, Weinstein GD (1995): Treatment of psoriasis. N Engl J Med 332: 581–588.PubMedCrossRefGoogle Scholar
  54. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC (2000): A systematic review of treatments for severe psoriasis. Health Technol. Assess. 4:1–125.PubMedGoogle Scholar
  55. Grimme H, Augustin M (1999): Phytotherapie bei chronischen Dermatosen und Wunden: Was ist gesichert? Forsch. Komplementärmed 6(suppl 2): 5–8.PubMedGoogle Scholar
  56. Guenther LC (2004): Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol 5: 71–77.PubMedCrossRefGoogle Scholar
  57. Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993): Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermatitis 28: 81–83.PubMedCrossRefGoogle Scholar
  58. Harding KG, Morris HL, Patel GK (2002): Healing chronic wounds. Br Med J 324: 160–163.CrossRefGoogle Scholar
  59. Henz BM, Jablonska S, van de Kerkhof PC, Stingl G, Blaszczyk M, Vandervalk PG et al. (1999): Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 140: 685–688.PubMedCrossRefGoogle Scholar
  60. Hoare C, Li Wan Po A, Williams H (2000): Systematic review of treatments for atopic eczema. Health Technol Assess 4:1–191.PubMedGoogle Scholar
  61. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN (2003): Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149: 363–369.PubMedCrossRefGoogle Scholar
  62. Hölzle E (1984): Therapie der Hyperhidrosis. Hautarzt 35: 7–15.Google Scholar
  63. Hoffmann R, Happle R (2000): Current understanding of androgenetic alopecia. Part II: clinical aspects and treatment. Eur J Dermatol 10:410–417.PubMedGoogle Scholar
  64. Hornstein OP (1997): Glukokortikosteroide in der Dermatologie: Tag-und Nacht-Therapie vergessen. Dtsch Ärztebl 94: A–678.Google Scholar
  65. Hornstein OP, Nürnberg E (Hrsg) (1985): Externe Therapie von Hautkrankheiten. Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart New York.Google Scholar
  66. Jarvis B, Figgitt DP (2003): Topical 3% diclofenac in 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4:203–213.PubMedCrossRefGoogle Scholar
  67. Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K et al. (1999): Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquir Immune Defic Syndr 21:301–306.PubMedCrossRefGoogle Scholar
  68. Jemec GBE, Østerlind A (1994): Cancer in patients treated with coal tar: a long-term follow up study. J Eur Acad Dermatol Venerol 3:153–156.CrossRefGoogle Scholar
  69. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999): Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011.PubMedGoogle Scholar
  70. Karlsmark T, Agerslev RH, Bendz SH, Larsen JR, Roed-Petersen J, Andersen KE (2003): Clinical perormance of a new silver dressing, Contreet Foam, for chronic exuding venous leg ulcers. J Wound Care 12:351–354.PubMedGoogle Scholar
  71. Kawaguchi M, Mitsuhashi Y, Kondo S (2003): Iatrogenic hypercalcemia due to vitamin D3 ointment (l,24(OH2D3) combined with thiazide diuretics in a case of psoriasis. J Dermatol 30: 801–804.PubMedGoogle Scholar
  72. Kess D, Peters T, Meixner D, Scharffetter-Kochanek K (2003): Die Rolle von T-Zellen bei der Pathogenese der Psoriasis vulgaris. Haut 14:18–21.Google Scholar
  73. Knapp U (1995): Grundlagen der Wundheilung und Wundbehandlung. Med Monatsschr Pharm 18: 219–230.PubMedGoogle Scholar
  74. Koning S, Verhagen A, Suijlekom-Smit L, Butler C, Wouden J (2004): Interventions for impetigo (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.Google Scholar
  75. Körting HC (1995): Dermatotherapie: ein Leitfaden. Springer-Verlag, Berlin Heidelberg New York.CrossRefGoogle Scholar
  76. Korting HC, Schäfer-Korting M., Klövekorn W, Klövekorn G., Martin C, Laux P. (1995): Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Eur J Clin Pharmacol 48:461–465.PubMedCrossRefGoogle Scholar
  77. Koytchev R, Alken RG, Dundarov S (1999): Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis. Phytomedicine 6:225–230.PubMedCrossRefGoogle Scholar
  78. Lamba S, Lebwohl M (2001): Combination therapy with vitamin D analogues. Br. J. Dermatol. 144(Suppl. 58): 27–32.PubMedGoogle Scholar
  79. Langner A, Stapór W, Ambroziak M (2001): Efficacy and tolerance of topical calci-triol 3 microg g(-l) in psoriasis treatment: a review of our experience in Poland. Br J Dermatol 144(Suppl 58): 11–16.PubMedGoogle Scholar
  80. Landsdown AB (2004): A review of the use of silver in wound care: facts and fallacies. Br J Nurs 13(6 Suppl): S6–S19.Google Scholar
  81. Lebwohl M (1999): The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38:16–24.PubMedCrossRefGoogle Scholar
  82. Lebwohl M (2002): Should we switch from combination UVA/UVB phototherapy units to narrowband UVB? Photodermal. Photoimmunol. Photomed 18:44–46.CrossRefGoogle Scholar
  83. Lemmer B, Brune K (Hrsg.) (2004): Pharmakotherapie, klinische Pharmakologie, 12. Aufl. Springer-Verlag, Heidelberg.Google Scholar
  84. Leung DYM (2001): Atopic dermatitis and the immune system: The role of superantigens and bacteria. J Am Acad Dermatol 45: S13–S16.PubMedCrossRefGoogle Scholar
  85. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF (2001): The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 5:37–42.PubMedGoogle Scholar
  86. Loewe R, Pillinger M, de Martin R, Mrowietz U, Groger M, Holnthoner W. et al. (2001): Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol 117: 1363–1368.PubMedCrossRefGoogle Scholar
  87. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D et al. (2002): Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 168:4781–4787.PubMedGoogle Scholar
  88. Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996): Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35: 1021–1026.PubMedCrossRefGoogle Scholar
  89. Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ et al. (1997): Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 37:590–595.PubMedCrossRefGoogle Scholar
  90. Lunan HN (1975): Topical treatment of the burn patient. Am J Hosp Pharm 32: 599–605.PubMedGoogle Scholar
  91. Maddin S (Hrsg) (1991): Current Dermatologic Therapy, 2nd ed. W.B. Saunders Comp., Philadelphia.Google Scholar
  92. Maddin S (1999): A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 40: 961–965.PubMedCrossRefGoogle Scholar
  93. Maiche AG, Gröhn P, Mäki-Hokkonen H (1991): Effect of chamomille cream and almond ointment on acute radiation skin reaction. Acta Oncol 30: 395–396.PubMedCrossRefGoogle Scholar
  94. Mason J, Mason AR, Cork MJ (2002): Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146: 351–364.PubMedCrossRefGoogle Scholar
  95. McClellan KJ, Noble S (2000): Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1:191–199.PubMedCrossRefGoogle Scholar
  96. Merk HF, Bickers DR (1992): Dermatopharmakologie und Dermatotherapie. Black-well, Berlin.Google Scholar
  97. Murdoch D, Clissold SP (1992): Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 43:415–429.PubMedCrossRefGoogle Scholar
  98. Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001): Mutschier Arzneimittelwirkungen, 8. Auflage. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.Google Scholar
  99. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN J, van Dijk E (1989): Systemic therapy with fumaric acid derivatives: New possibilities in the treatment of psoriasis. J Am Acad Dermatol 20:601–608.PubMedCrossRefGoogle Scholar
  100. Niedner R (1998): Kortikoide in der Dermatologie. UNI-MED Verlag, Bremen.Google Scholar
  101. Niedner R (2003): Topische Kortikoide versus Calcineurinantagonisten. Hautarzt 54: 338–341.PubMedGoogle Scholar
  102. Niedner R, Ziegenmeyer J (Hrsg) (1992): Dermatika. Therapeutischer Einsatz, Pharmakologie und Pharmazie. Wissenschaftliche Verlagsgesellschaft, Stuttgart.Google Scholar
  103. NN (1997): Therapie der schweren Psoriasis mit Fumaraten. Arzneimittelbrief 31: 57–59.Google Scholar
  104. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D (1990): Fuma-ric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 22: 311–312.PubMedCrossRefGoogle Scholar
  105. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M (1998): The antipso-riatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine work. Br J Dermatol 139: 390–395.PubMedCrossRefGoogle Scholar
  106. Orfanos CE, Vogels L (1980): Lokaltherapie der Alopecia androgenetica mit 17a-Östradiol. Eine kontrollierte, randomisierte Doppelblindstudie. Dermatologica 161: 124–132.PubMedCrossRefGoogle Scholar
  107. Ormerod AD, Mrowietz U (2004): Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 150: 630–632.PubMedCrossRefGoogle Scholar
  108. Patel B, Siskin S, Krazmien R, Lebwohl M (1998): Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 38: 1010–1011.PubMedCrossRefGoogle Scholar
  109. Peters DC, Balfour JA (1997): Tacalcitol. Drugs 54:265–271.PubMedCrossRefGoogle Scholar
  110. Petersen EE, Doerr HW, Gross G, Petzoldt D, Weissenbacher ER, Wutzier P (1999): Der Herpes genitalis. Dtsch Ärztebl 96: A-2358–A2364.Google Scholar
  111. Pfannschmidt N, Bauer R, Kreysel HW (1988): Die topische Kombinationstherapie der Akne mit Erythromycin und Tretinoin. Z Hautkr 63: 366–368.PubMedGoogle Scholar
  112. Post B, Jänner M (1971): Zur Indikation der Gerbstofftherapie in der Dermatologie. Klinische Erfahrungen mit Tannosynt. Ther Ggw 110: 1477–1494.PubMedGoogle Scholar
  113. Prinz JC (2003): Neueste Aspekte in der Pathogenese der Psoriasis. Hautarzt 54: 209–214.PubMedGoogle Scholar
  114. Proske S, Uter W, Schnuch A, Hartschuh W (2003): Schwere allergische Kontaktder-matitis mit generalisierter Streuung auf Bufexamac unter dem Bild eines „Baboon“-Syndroms. Dtsch Med Wochenschr 128: 545–547.PubMedCrossRefGoogle Scholar
  115. Raab W (1984): Psoriasis-Behandlung mit Fumarsäure und Fumarsäureestern. Z Hautkr 59: 671–679.PubMedGoogle Scholar
  116. Raborn GW, McGaw WT, Grace M, Eng P, Percy J, Samuels S (1989): Herpes labialis treatment with acyclovir 5% modified aqueous cream: A double-blind, randomized trial. Oral Surg. Oral Med Oral Pathol Oral Radiol Endod 67: 676–679.Google Scholar
  117. Rebora A (2002): The management of rosacea. Am J Clin Dermatol 3: 489–496.PubMedCrossRefGoogle Scholar
  118. Ring J, Fröhlich HH (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl, Springer-Verlag, Berlin Heidelberg.CrossRefGoogle Scholar
  119. Rizova E, Corroller M (2001): Topical calcitriol — studies on local tolerance and systemic safety. Br J Dermatol 144(Suppl 58): 3–10.PubMedGoogle Scholar
  120. Sadique J, Chandra T, Thenmozhi V, Elango V (1987): Biochemical modes of action of Cassia occidentalis and Cardiospermum halicacabum in inflammation. J Ethnopharmacol 19: 201–212.PubMedCrossRefGoogle Scholar
  121. Savin JA (1985): Some guidelines to the use of topical corticosteroids. Brit Med J 290: 1607–1608.CrossRefGoogle Scholar
  122. Schäfer-Körting M, Schmid MH, Körting HC (1996): Topical glucocorticoids with improved risk-benefit ratio. Drug Safety 14: 375–385.PubMedCrossRefGoogle Scholar
  123. Scharfetter-Kochanek K, Meewes C, Eming S, Dissemond J, Hani N, Wenk J, Wla-schek M, Brenneisen P (1999): Chronische Wunden und Wachstumsfaktoren. Zeitschr. Hautkrankh. H+G 11:664–672.Google Scholar
  124. Schulze-Dirks A, Frosch PJ (1988): Kontaktallergie auf Dexpanthenol. Hautarzt 39: 375–377.PubMedGoogle Scholar
  125. Seböck B, Bonnekoh B, Geisel J, Mahrle G (1994): Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 270: 79–87.Google Scholar
  126. Shah M, Mohanraj M (2003): High levels of fusidic acid-resistent Staphylococcus aureus in dermatology patients. Br J Dermatol 148:1018–1020.PubMedCrossRefGoogle Scholar
  127. Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D, International Wound Bed Preparation Advisory Board, Canadian Chronic Wound Advisory Board (2003): Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 49: 23–51.PubMedGoogle Scholar
  128. Simon C, Stille W (2000): Antibiotika-Therapie in Klinik und Praxis, 10. Aufl, Schattauer, Stuttgart New York.Google Scholar
  129. Spruance SI, Kriesel JD (2002): Treatment of herpes simplex labialis. Herpes 9: 64–69.PubMedGoogle Scholar
  130. Steele K, Shirodaria P, O’Hare M, Merrett JD, Irwin WG, Simpson DI, Pfister H (1988): Monochloroacetic acid and 60% salicylic acid as a treatment for simple plantar warts: effectiveness and mode of action. Br J Dermatol 118: 537–543.PubMedCrossRefGoogle Scholar
  131. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM (2001): The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 144:1114–1120.PubMedCrossRefGoogle Scholar
  132. Strömberg HE, Ägren MS (1984): Topical zinc oxide treatment improves arterial and venous leg ulcers. Br J Dermatol 111: 461–468.PubMedCrossRefGoogle Scholar
  133. Sweetman SC (ed) (2002): Martindale: The Complete Drug Reference, 33rd ed, Pharmaceutical Press, London.Google Scholar
  134. Sykes NL, Webster GF (1994): Acne. A review of optimum treatment. Drugs 48: 59–70.PubMedCrossRefGoogle Scholar
  135. Tan H-H (2004): Topical antibacterial treatments for acne vulgaris. Comparative review and guide to selection. Am J Clin Dermatol 5: 79–84.PubMedCrossRefGoogle Scholar
  136. Thio HB, Zomerdijk TPL, Oudshoorn C, Kempenaar J, Nibbering PH, van der Schroeff JG, Ponec M (1994): Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Br J Dermatol 131: 856–861.PubMedCrossRefGoogle Scholar
  137. Trauner MA, Ruben BS (1999): Isotretinoin induced rhabdomyolysis? A case report. Dermatol Online J. 5:2.PubMedGoogle Scholar
  138. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R (1998): A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil 19: 531–537.PubMedCrossRefGoogle Scholar
  139. Tronnier H, Haas PJ, Zimmermann T (1990): Wirksamkeit und Wirkungsmechanismus von Isoprenalinsulfat und Clemastinhydrogenfumarat auf durch Hista-min-Quaddelung ausgelösten Juckreiz. Eine Plazebo-kontrollierte Probandenstudie. Derm Beruf Umwelt 38:15–18.PubMedGoogle Scholar
  140. Trozak DJ (1999): Topical corticosteroid therapy in psoriasis vulgaris: Update and new strategies. Cutis 64: 315–318.PubMedGoogle Scholar
  141. Van de Kerkhof PCM, Vissers WHPM (2003): The topical treatment of psoriasis. Skin Pharmacol Skin Physiol 16: 69–83.CrossRefGoogle Scholar
  142. Vandermeeren M, Janssens S, Borgers M, Geysen J (1997): Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 234: 19–23.PubMedCrossRefGoogle Scholar
  143. Van Zuuren E, Graber M, Hollis S, Chaudry M, Gupta AK (2004): Interventions for rosacea (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.Google Scholar
  144. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB (1997): Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 137: 581–586.PubMedCrossRefGoogle Scholar
  145. Walluf-Blume D (1991): Aufbereitung und Nachzulassung von OTC-Arzneimitteln in den USA 1990. Pharm Ind 53: 152–158.Google Scholar
  146. Ward A, Campoli-Richards DM (1986): Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 32: 425–444.PubMedCrossRefGoogle Scholar
  147. Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG (1999): Suberythemo-genic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 40: 893–900.PubMedCrossRefGoogle Scholar
  148. Warnecke J, Wendt A (1998): Anti-inflammatory action of pale sulfonated shale oile (ICHTHYOL pale) in UVB erythema test. Inflamm Res 47: 75–78.PubMedCrossRefGoogle Scholar
  149. Wilkinson JD (1998): Fusidic acid in dermatology. Br J Dermatol 139(Suppl 53): 37–40.PubMedCrossRefGoogle Scholar
  150. Williams H (2002): New treatments for topic dermatitis. Brit Med J 324: 1533–1534.PubMedCrossRefGoogle Scholar
  151. Wolf-Jürgensen P (1979): Efficacy of bufexamac cream versus betamethasone valerate cream in contact dermatitis: a double-blind trial. Curr Med Res Opin 5: 779–784.PubMedCrossRefGoogle Scholar
  152. Wrigth JB, Lam K, Burrell RE (1998): Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control 26: 572–577.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Uwe Fricke
    • 1
  1. 1.Institut für Pharmakologie der Universität zu KölnKöln

Personalised recommendations